Payment overview · 2025
General Payments
$407.70
22 reported records · 10 companies
Healthcare provider profile · identity verified
Kayla Babb, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SIKESTON, MO · NPI 1508484890
Verified facts
What the public records show
CMS Open Payments records show Kayla Babb, FNP received $407.70 in general payments during 2025 across 22 reported records.
Alkermes, Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lybalvi, Rexulti.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lybalvi by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $87.91 | 21.6% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.31 | 15.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $58.94 | 14.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $57.92 | 14.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.34 | 9.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.12 | 7.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.19 | 5.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.72 | 5.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.97 | 3.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.28 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $369.16 | 21 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $87.91 | 5 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $87.91 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $63.31 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $58.94 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $57.92 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.12 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 524 | 51 |
| Furosemide | Furosemide | 292 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 269 | 33 |
| Eliquis | Apixaban | 263 | 24 |
| Gabapentin | Gabapentin | 256 | 33 |
| Mirtazapine | Mirtazapine | 241 | 36 |
| Buspirone Hcl | Buspirone Hcl | 239 | 27 |
| Lorazepam | Lorazepam | 217 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 38 |
| Potassium Chloride | Potassium Chloride | 194 | 22 |
| Torsemide | Torsemide | 188 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 22 |
| Lisinopril | Lisinopril | 151 | 23 |
| Omeprazole | Omeprazole | 142 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 19 |
| Tramadol Hcl | Tramadol Hcl | 114 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 98 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 90 | 15 |
| Carvedilol | Carvedilol | 87 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 12 |
| Allopurinol | Allopurinol | 82 | suppressed |
| Levetiracetam | Levetiracetam | 78 | suppressed |
| Baclofen | Baclofen | 77 | suppressed |
| Metformin Hcl | Metformin Hcl | 76 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 11 |
| Donepezil Hcl | Donepezil Hcl | 75 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | suppressed |
| Sucralfate | Sucralfate | 73 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 73 | suppressed |
| Famotidine | Famotidine | 72 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 67 | 11 |
| Levofloxacin | Levofloxacin | 65 | 52 |
| Azithromycin | Azithromycin | 61 | 29 |
| Ondansetron Odt | Ondansetron | 61 | 15 |
| Pregabalin | Pregabalin | 60 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 57 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Nystatin | Nystatin | 55 | 20 |
| Losartan Potassium | Losartan Potassium | 54 | suppressed |
| Clonazepam | Clonazepam | 53 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 18 |
| Sertraline Hcl | Sertraline Hcl | 48 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 42 |
| Invokana | Canagliflozin | 45 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 42 | 15 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 30 |
| Diazepam | Diazepam | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 14 |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 31 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 30 | 12 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 26 | 21 |
| Digoxin | Digoxin | 26 | suppressed |
| Lacosamide | Lacosamide | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Nystop | Nystatin | 21 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Fluconazole | Fluconazole | 19 | 14 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 17 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Neupro | Rotigotine | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | 12 |
| Methimazole | Methimazole | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $407.70 · 22 records | Alkermes, Inc. | ARISTADA, BREZTRI, CAPLYTA, FANAPT, INGREZZA, Kerendia, LYBALVI, REXULTI, The Cologuard Plus Collection Kit, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lybalvi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error